Evaluation and registration of adverse events in clinical drug trials in migraine

Cephalalgia

Volumn 28, Issue 7, 2008, Pages 683-688

  Tfelt Hansen, P ^a,g   Bjarnason, N H ^b   Dahlof C ^c   Derry, S ^d   Loder, E ^e   Massiou, H ^f  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HÔPITAL LARIBOISIÈRE   (France)

^g GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adverse events; Assessment; Migraine; Reporting

Indexed keywords

CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MIGRAINE; QUESTIONNAIRE; REVIEW; WELLBEING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES;

EID: 44849135183     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01600.x     Document Type: Review

References (24)

1. International Headache Society Clinical Trial Subcommittee. Guidelines for controlled trials of drugs in migraine : second edition. Cephalalgia 2000 20 : 765 86.
2. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004 291 : 965 73.
3. Silberstein SD, Neto W, Jacobs D MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004 61 : 490 5.
4. Diener HC, Tfelt-Hansen P, Dahlöf C, Lainez MJA, Sandrini G, Wang S-J et al. Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propranolol as an active control. Eur Neurol 2004 251 : 943 50.
5. Guberman A, Neto W, Gassman-Mayer C. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002 106 : 183 9.
6. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 107 : 165 75.
7. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005 28 : 851 70.
8. Dahlöf C. Minor Symptoms Evaluation (MSE) Profile - a questionnaire for assessment of subjective CNS-related symptoms. Scand J Prim Health Care Suppl 1990 1 : 19 25.
9. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
10. Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW. The Henry Ford Hospital. Headache Disability Inventory (HDI). Neurology 1994 44 : 837 42.
11. Wagner TH, Patrick DL, Galer BS, Berzon RA. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 1996 36 : 484 92.
12. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998 38 : 295 302.
13. Stewart WF, Lipton RB, Simon D, Von Korff M, Liberman J. Reliability of an illness severity measure for headache in a population sample of migraine sufferers. Cephalalgia 1998 18 : 44 51.
14. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005 25 : 124 31.
15. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004 62 : 23 7.
16. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M Topiramate TPS-TR Study Group. Topiramate titration and tolerability. Ann Pharmacother 2001 35 : 173 9.
17. Ware J Jr., Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 34 : 220 33.
18. Dupuy HJ. The psychological general well-being (PGWB) index. In : Wenger NK, Mattson ME, Furberg CD, Elinson JE, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York : Le Jacq Publishing 1984 : 170 80.
19. Grossi E, Groth N, Mosconi P, Cerutti R, Pace F, Compare A, Apolone G. Developement and validation of the short version of the Psychological General Well-Being Index (PGWB-S). Health Qual Life Outcomes 2006 4 : 88.
20. Dimenäs ES, Wiklund IK, Dahlöf CG, Lindvall KG, Olofsson BK, De Faire UH. Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989 7 : 885 90.
21. Dahlöf C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine - with regard to both efficacy and general well-being. Cephalalgia 1992 12 : 214 20.
22. Dahlöf C. Assessment of health-related quality of life in migraine. Cephalalgia 1993 13 : 233 7.
23. Bjorner JB, Kosinski M, Waere JE Jr. Using item response therapy to calibrate the Headache Impact Test (HIT) to the metric of traditional headache scales. Qual Life Res 2003 12 : 981 1002.
24. Goadsby PJ, Dodick D, Almas M, Diener H-C, Tfelt-Hansen P, Lipton RB, Parsson B. Treatment emergent CNS symptoms following triptan therapy are part of the migraine attack. Cephalalgia 2007 27 : 254 62.